Abhishek Maiti

Data from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Aram Bidikian, Carvalho Manuel et autres

Supplementary Data 1 from Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Aram Bidikian, Carvalho Manuel et autres

Combination therapy with Nelarabine, Pegaspargase and Venetoclax for Adults Patients with R/R T-cell ALL/LBL

Niranjan Khaire, Elias Jabbour, Tapan Kadia, Nicholas J. Short et autres

us (code pays fourni par la source)

Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies

Yuki Nishida, Valeria Impedovo, Edward Ayoub, Natalia Baran et autres

us, ch, jp, cn, de (code pays fourni par la source)

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia

Elias Jabbour, Caitlin R. Rausch, Hannah Goulart, Nitin Jain et autres

us (code pays fourni par la source)

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study

Nicholas J. Short, Alex Bataller, Courtney D. DiNardo, Guillermo Montalban-Bravo et autres

us (code pays fourni par la source)

Investigational Clinical Trial Agents versus Conventional Second Salvage Therapies in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Daniel Nguyen, Hagop M. Kantarjian, Aram Bidikian, Carvalho Manuel et autres

us (code pays fourni par la source)

RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

Anudishi Tyagi, Maryam Siddiqui, Amanda Eckstrom, Isabel Kurth et autres

us (code pays fourni par la source)

Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AML

Jennifer Marvin-Peek, Hagop Kantarjian, Wei‐Ying Jen, Naval Daver et autres

us (code pays fourni par la source)

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome

Courtney D. DiNardo, Jennifer Croden, Hiam M. Abdel‐Salam, Tapan Kadia et autres

us (code pays fourni par la source)

A Phase II open-label study of Olutasidenib Post-Transplant Maintenance Therapy for Patients with IDH1-Mutated Myeloid Malignancies

Jeremy Ramdial, Kelly Chien, Betul Oran, Rohtesh S. Mehta et autres

us (code pays fourni par la source)

Global Epidemiologic Trends of Early-Onset Cancers From 1990 to 2021 and Projection to 2040

Rupayan Kundu, Ankush Mukhopadhyay, Niladri Kal, Tuhin Subhra Pal et autres

us, in (code pays fourni par la source)